Enhance your patient care.
Gain higher reimbursements with the CANS-MCI.
Experience the precision and accuracy of Screen, Inc’s leading-edge Computer-Administered Neuropsychological Screen for Mild Cognitive Impairment
Neurological Complications of COVID-19Patients who survive COVID-19 are at high risk of neurological decline. The CANS-MCI has been shown to predict both elevated Aβ and tau — both associated with COVID-19 infections. Our tests capture the most important dimensions for evaluating the cognitive effects of COVID-19.
Preclinical Diagnosis of ADBiomarker research finds CANS-MCI performance predicts both elevated Aβ and tau. The CANS-MCI captures item-level response times at millisecond accuracy and can detect patterns of delay associated with the preclinical stage of AD. To read more about this research, click here.
Tracking "Chemo Brain"When cognitive and emotional changes associated with cancer treatment are important to evaluate, baseline data can be compared with post-treatment testing. The CANS-MCI provides the most staff-efficient, objective, longitudinal assessment of cognitive change available today.
Concussion AssessmentThe central changes in cognitive ability due to sports concussion are memory, cognitive processing speed, and reaction time — all measured at millisecond accuracy by the CANS-MCI. Our automated test also eliminates the potential for the deliberate or unaware bias of in-person testers.